| 1 | Adaptive Judo and neuropathy: a mini review on motor skills, balance, and quality of life improvement | 1.6 | 0 | Citations (PDF) |
| 2 | Prevalence of cognitive impairment in motor neuron diseases: alternative norming methods lead to considerably diverse estimates | 1.7 | 1 | Citations (PDF) |
| 3 | Increased [18F]DPA-714 Uptake in the Skeletal Muscle of SOD1G93A Mice: A New Potential of Translocator Protein 18 kDa Imaging in Amyotrophic Lateral Sclerosis | 3.3 | 3 | Citations (PDF) |
| 4 | A Comprehensive Description of the Roadmap to Identify and Validate a Myelin Biomarker | 0.9 | 1 | Citations (PDF) |
| 5 | Top bar navigation | 1.6 | 2 | Citations (PDF) |
| 6 | Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants | 2.3 | 7 | Citations (PDF) |
| 7 | Log in to my account | 2.0 | 2 | Citations (PDF) |
| 8 | Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder | 2.4 | 1 | Citations (PDF) |
| 9 | Log in to my account | 1.8 | 2 | Citations (PDF) |
| 10 | Monitoring Myelin Lipid Composition and the Structure of Myelinated Fibers Reveals a Maturation Delay in CMT1A | 3.3 | 8 | Citations (PDF) |
| 11 | Mild behavioral impairment as a potential marker of predementia risk states in motor neuron diseases | 2.3 | 15 | Citations (PDF) |
| 12 | Frequency, entity and determinants of fatigue in Charcot–Marie–Tooth disease | 2.3 | 15 | Citations (PDF) |
| 13 | Using Cluster Analysis to Overcome the Limits of Traditional Phenotype–Genotype Correlations: The Example of RYR1-Related Myopathies | 1.9 | 5 | Citations (PDF) |
| 14 | CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome | 0.7 | 52 | Citations (PDF) |
| 15 | Comparing the Impact of COVID-19 on Vaccinated and Unvaccinated Patients Affected by Myasthenia Gravis | 2.2 | 4 | Citations (PDF) |
| 16 | Recurrent Motor Branch Neuropathy in Carpal Tunnel Syndrome: An Ultrasonography Study | 0.7 | 0 | Citations (PDF) |
| 17 | Recurrent motor branch neuropathy in carpal tunnel syndrome: An ultrasound study | 1.6 | 8 | Citations (PDF) |
| 18 | An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia | 1.6 | 22 | Citations (PDF) |
| 19 | Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion | 2.4 | 24 | Citations (PDF) |
| 20 | Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations | 3.6 | 43 | Citations (PDF) |
| 21 | Robot-assisted and traditional intensive rehabilitation therapy in the treatment of post-acute stroke patient: the experience of a standard rehabilitation ward | 1.2 | 1 | Citations (PDF) |
| 22 | Predicting Outcome in Guillain-Barré SyndromeInternational Validation of the Modified Erasmus GBS Outcome Score | 0.7 | 71 | Citations (PDF) |
| 23 | Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments | 1.2 | 3 | Citations (PDF) |
| 24 | MND Phenotypes Differentiation: The Role of Multimodal Characterization at the Time of Diagnosis | 2.2 | 5 | Citations (PDF) |
| 25 | Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy | 4.4 | 28 | Citations (PDF) |
| 26 | Top bar navigation | 1.6 | 8 | Citations (PDF) |
| 27 | CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS | 4.4 | 37 | Citations (PDF) |
| 28 | Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria? | 2.3 | 19 | Citations (PDF) |
| 29 | Predictors of self-perceived health worsening over COVID-19 emergency in ALS | 1.2 | 9 | Citations (PDF) |
| 30 | Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy | 0.3 | 2 | Citations (PDF) |
| 31 | Dysregulation of myelin synthesis and actomyosin function underlies aberrant myelin in CMT4B1 neuropathy | 5.4 | 23 | Citations (PDF) |
| 32 | The neurophysiological lesson from the Italian CIDP database | 1.2 | 3 | Citations (PDF) |
| 33 | Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP | 2.9 | 4 | Citations (PDF) |
| 34 | Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity | 0.7 | 35 | Citations (PDF) |
| 35 | Neuropathic pain and symptoms of potential small-fiber neuropathy in fibromyalgic patients: A national on-line survey | 1.9 | 39 | Citations (PDF) |
| 36 | Detection of movement related cortical potentials in freehand drawing on digital tablet | 1.8 | 5 | Citations (PDF) |
| 37 | A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection | 1.8 | 7 | Citations (PDF) |
| 38 | Abnormal sweating and “skin flushing” as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature | 1.3 | 2 | Citations (PDF) |
| 39 | Charcot-Marie-Tooth neuropathy score and ambulation index are both predictors of orthotic need for patients with CMT | 1.2 | 8 | Citations (PDF) |
| 40 | Douleurs neuropathiques et symptômes évoquant une neuropathie des petites fibres chez des patients atteints de fibromyalgie : enquête nationale en ligne | 0.0 | 0 | Citations (PDF) |
| 41 | Parsonage–Turner syndrome following coronavirus disease 2019 immunization with ChAdOx1-S vaccine: a case report and review of the literature | 0.5 | 27 | Citations (PDF) |
| 42 | Treadmill training in patients affected by Charcot–Marie–Tooth neuropathy: results of a multicenter, prospective, randomized, single-blind, controlled study | 2.3 | 33 | Citations (PDF) |
| 43 | High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial | 1.7 | 13 | Citations (PDF) |
| 44 | People also looked at | 1.6 | 47 | Citations (PDF) |
| 45 | The suspected SARS-Cov-2 infection in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value of telerehabilitation for evaluation and continuing treatment : International Journal of Rehabilitation Research | 0.6 | 11 | Citations (PDF) |
| 46 | hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers | 1.9 | 37 | Citations (PDF) |
| 47 | COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy | 1.3 | 21 | Citations (PDF) |
| 48 | Pregnancy in Charcot-Marie-Tooth diseaseData from the Italian CMT national registry | 0.7 | 23 | Citations (PDF) |
| 49 | Screening for Fabry disease in unknown origin axonal polyneuropathy: to do or not to do, this is the question! | 1.9 | 5 | Citations (PDF) |
| 50 | Distal motor neuropathy associated with novel mutation | 3.6 | 18 | Citations (PDF) |
| 51 | Bendamustine–rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy | 1.3 | 15 | Citations (PDF) |
| 52 | Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature | 1.2 | 10 | Citations (PDF) |
| 53 | Request of hospital care dropped for TIA but remained stable for stroke during COVID-19 pandemic at a large Italian university hospital | 2.4 | 8 | Citations (PDF) |
| 54 | High-dose immunoglobulin pulse therapy and risk of Covid19 infection | 2.9 | 7 | Citations (PDF) |
| 55 | High-Resolution Ultrasound of Small Clinically Relevant Nerves Running Across the Posterior Triangle of the Neck | 0.7 | 12 | Citations (PDF) |
| 56 | Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase | 0.9 | 27 | Citations (PDF) |
| 57 | Comparison of Strength and Dexterity in Professional and Student Violinists: Setting Foundations to Guide Rehabilitation | 0.3 | 2 | Citations (PDF) |
| 58 | “Limbic encephalitis with acute onset and Hu antibodies treated with rituximab: Paraneoplastic or non-paraneoplastic disorder?” | 1.0 | 2 | Citations (PDF) |
| 59 | Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment | 1.9 | 51 | Citations (PDF) |
| 60 | Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity | 1.9 | 54 | Citations (PDF) |
| 61 | A novel mutation in the N-terminal acting-binding domain of Filamin C protein causing a distal myofibrillar myopathy | 1.3 | 10 | Citations (PDF) |
| 62 | A multicenter retrospective study of charcot-marie-tooth disease type 4B (CMT4B) associated with mutations in myotubularin-related proteins (MTMRs) | 4.8 | 37 | Citations (PDF) |
| 63 | Are novel outcome measures for Charcot–Marie–Tooth disease sensitive to change? The 6-minute walk test and StepWatch™ Activity Monitor in a 12-month longitudinal study | 0.3 | 9 | Citations (PDF) |
| 64 | People also looked at | 1.6 | 14 | Citations (PDF) |
| 65 | Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database | 4.4 | 137 | Citations (PDF) |
| 66 | Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study | 1.2 | 22 | Citations (PDF) |
| 67 | The primary role of radiological imaging in the diagnosis of rare musculoskeletal diseases. Emphasis on ultrasound. | 0.9 | 4 | Citations (PDF) |
| 68 | A cross-sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy | 3.2 | 79 | Citations (PDF) |
| 69 | Autosomal-dominant transthyretin (TTR)-related amyloidosis is not a frequent CMT2 neuropathy “in disguise” | 1.9 | 2 | Citations (PDF) |
| 70 | Electromyographic and biomechanical analysis of step negotiation in Charcot Marie Tooth subjects whose level walk is not impaired | 0.8 | 7 | Citations (PDF) |
| 71 | Remarkable Rituximab Response on Tremor Related to Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy in an Antineurofascin155 Immunoglobulin G4–Seropositive Patient | 1.3 | 9 | Citations (PDF) |
| 72 | A novel prion protein gene-truncating mutation causing autonomic neuropathy and diarrhea | 2.3 | 7 | Citations (PDF) |
| 73 | High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy | 1.2 | 3 | Citations (PDF) |
| 74 | Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A | 4.4 | 24 | Citations (PDF) |
| 75 | Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies | 2.8 | 33 | Citations (PDF) |
| 76 | Responsiveness of gait analysis parameters in a cohort of 71 CMT subjects | 0.3 | 15 | Citations (PDF) |
| 77 | l-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain | 4.0 | 15 | Citations (PDF) |
| 78 | Dysimmune mononeuropathies: A diagnosis not to be missed | 1.6 | 2 | Citations (PDF) |
| 79 | Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy | 3.6 | 33 | Citations (PDF) |
| 80 | Sacral nerve stimulation for fecal incontinence in a patient with anti-phospholipid syndrome–related autonomic neuropathy | 1.6 | 0 | Citations (PDF) |
| 81 | Alternative Splicing in the Human PMP22 Gene: Implications in CMT1A Neuropathy | 1.0 | 14 | Citations (PDF) |
| 82 | Guillain-Barré syndrome following chickenpox: a case series | 1.3 | 10 | Citations (PDF) |
| 83 | The Transcription Factors EBF1 and EBF2 Are Positive Regulators of Myelination in Schwann Cells | 3.2 | 13 | Citations (PDF) |
| 84 | High Dose Intravenous Immunoglobulin is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double Blind, Randomized, Placebo-Controlled, Multicenter Trial. (P2.268) | 0.7 | 0 | Citations (PDF) |
| 85 | Sural nerve biopsy and functional studies support the pathogenic role of a novel MPZ mutation | 0.7 | 3 | Citations (PDF) |
| 86 | Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response | 3.0 | 3 | Citations (PDF) |
| 87 | Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP | 4.4 | 84 | Citations (PDF) |
| 88 | Levodopa-induced neutropenia | 2.0 | 8 | Citations (PDF) |
| 89 | Brown-Vialetto-Van Laere syndrome: Clinical and neuroradiological findings of a genetically proven patient | 1.7 | 17 | Citations (PDF) |
| 90 | PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker.Brain, 2014, 137, 1614-20 | 6.1 | 32 | Citations (PDF) |
| 91 | The Diadenosine Homodinucleotide P18 Improves In Vitro Myelination in Experimental Charcot-Marie-Tooth Type 1A | 1.9 | 11 | Citations (PDF) |
| 92 | Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. | 0.3 | 29 | Citations (PDF) |
| 93 | Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation | 1.8 | 27 | Citations (PDF) |
| 94 | Influence of comorbidities on the phenotype of patients affected by Charcot–Marie–Tooth neuropathy type 1A | 0.3 | 15 | Citations (PDF) |
| 95 | Sjögren’s syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT) | 2.6 | 20 | Citations (PDF) |
| 96 | Clinical epidemiology of ALS in Liguria, Italy | 1.7 | 22 | Citations (PDF) |
| 97 | Oxydative phosphorylation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy. | 2.8 | 17 | Citations (PDF) |
| 98 | Gain of glycosylation: A new pathomechanism of myelin protein zero mutations | 4.8 | 23 | Citations (PDF) |
| 99 | Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial | 25.9 | 210 | Citations (PDF) |
| 100 | Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain | 1.2 | 36 | Citations (PDF) |
| 101 | Outcome Measures and Rehabilitation Treatment in Patients Affected by Charcot-Marie-Tooth Neuropathy | 1.0 | 38 | Citations (PDF) |
| 102 | HSPB1 and HSPB8 in inherited neuropathies: study of an Italian cohort of dHMN and CMT2 patients | 1.9 | 62 | Citations (PDF) |
| 103 | Both Schwann cell and axonal defects cause motor peripheral neuropathy in −/− mice | 3.6 | 13 | Citations (PDF) |
| 104 | Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial | 25.9 | 248 | Citations (PDF) |
| 105 | Inherited Neuropathies | 0.8 | 42 | Citations (PDF) |
| 106 | A case of secondary syphilis presenting as optic neuritis | 1.2 | 24 | Citations (PDF) |
| 107 | The spectrum of GNE mutations: allelic heterogeneity for a common phenotype | 1.2 | 16 | Citations (PDF) |
| 108 | Diadenosine Homodinucleotide Products of ADP-ribosyl Cyclases Behave as Modulators of the Purinergic Receptor P2X7* | 1.4 | 11 | Citations (PDF) |
| 109 | P2X7-mediated Increased Intracellular Calcium Causes Functional Derangement in Schwann Cells from Rats with CMT1A Neuropathy * | 1.4 | 63 | Citations (PDF) |
| 110 | Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases | 1.2 | 60 | Citations (PDF) |
| 111 | Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy. | 1.5 | 15 | Citations (PDF) |
| 112 | Natural history of Charcot–Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of life | 1.2 | 18 | Citations (PDF) |
| 113 | Carcinoma of the tongue mimicking bulbar amyotrophic lateral sclerosis | 1.2 | 1 | Citations (PDF) |
| 114 | Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings | 1.2 | 34 | Citations (PDF) |
| 115 | Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura | 1.6 | 26 | Citations (PDF) |
| 116 | Correlation between clinical/neurophysiological findings and quality of life in Charcot-Marie-Tooth type 1A | 1.9 | 38 | Citations (PDF) |
| 117 | Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. | 2.2 | 69 | Citations (PDF) |
| 118 | Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Anti–Myelin-Associated Glycoprotein Polyneuropathy | 6.9 | 31 | Citations (PDF) |
| 119 | Peripheral Nerve Abnormalities | 0.3 | 22 | Citations (PDF) |
| 120 | Phenotypic characterization of hypomyelination and congenital cataract | 4.8 | 43 | Citations (PDF) |
| 121 | Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin M | 1.9 | 91 | Citations (PDF) |
| 122 | A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIL): The study protocol [EudraCT no.: 2006-000032-27] | 6.7 | 45 | Citations (PDF) |
| 123 | Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot–Marie–Tooth type 1A disease | 1.7 | 18 | Citations (PDF) |
| 124 | Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract | 14.9 | 95 | Citations (PDF) |
| 125 | GDAP1 mutation in autosomal recessive Charcot-Marie-Tooth with pyramidal features | 2.9 | 9 | Citations (PDF) |
| 126 | Quality of life and disability assessment in neuropathy: a multicentre study | 1.9 | 35 | Citations (PDF) |
| 127 | Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside.Brain, 2005, 128, 1168-77 | 6.1 | 114 | Citations (PDF) |
| 128 | Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network : new implications for Charcot-Marie-Tooth disease | 3.7 | 376 | Citations (PDF) |
| 129 | Experimental Charcot–Marie–Tooth type 1A: A cDNA microarrays analysis | 2.2 | 39 | Citations (PDF) |
| 130 | Synaptopodin and 4 novel genes identified in primary sensory neurons | 2.2 | 3 | Citations (PDF) |
| 131 | Peripheral nerves: a target for the action of neuroactive steroids | 5.9 | 95 | Citations (PDF) |
| 132 | Expression of ciliary neurotrophic factor (CNTF) in charcot-marie-tooth type 1A (CMT1A) disease | 1.9 | 0 | Citations (PDF) |
| 133 | Does parkin play a role in the peripheral nervous system? A family report | 3.3 | 35 | Citations (PDF) |
| 134 | Mycophenolate mofetil in dysimmune neuropathies: A preliminary study | 1.6 | 41 | Citations (PDF) |
| 135 | Progressive multifocal leukoencephalopathy in an adult patient with ICF syndrome | 1.3 | 16 | Citations (PDF) |
| 136 | Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease | 3.1 | 22 | Citations (PDF) |
| 137 | Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease | 3.6 | 35 | Citations (PDF) |
| 138 | Mifepristone (RU 38486) influences expression of glycoprotein Po and morphological parameters at the level of rat sciatic nerve: in vivo observations | 3.1 | 21 | Citations (PDF) |
| 139 | Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22 | 1.8 | 34 | Citations (PDF) |
| 140 | The D355V Mutation Decreases EGR2 Binding to an Element within the Cx32 Promoter | 3.6 | 26 | Citations (PDF) |
| 141 | Insulin treatment enhances expression of IGF-I in sural nerves of diabetic patients | 1.6 | 20 | Citations (PDF) |
| 142 | PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A | 4.8 | 21 | Citations (PDF) |
| 143 | Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2 | 14.9 | 451 | Citations (PDF) |
| 144 | Loss of large-diameter spindle afferent fibres is not detrimental to the control of body sway during upright stance: evidence from neuropathy | 1.2 | 82 | Citations (PDF) |
| 145 | An Italian family with Ala-47 transthyretin mutation associated with cardiomyopathy and polyneuropathy | 0.3 | 6 | Citations (PDF) |
| 146 | Exclusion of the ninjurin gene as a candidate for hereditary sensory neuropathies type I and type II | 1.1 | 3 | Citations (PDF) |
| 147 | Tyrosine kinase A-nerve growth factor receptor is antigenically present in dystrophic neurites from a variety of conditions but not in Alzheimer's disease | 1.4 | 5 | Citations (PDF) |
| 148 | Effect of Recombinant Human Nerve Growth Factor on Cisplatin Neurotoxicity in Rats | 3.1 | 50 | Citations (PDF) |
| 149 | Molecular basis of inherited neuropathies | 2.7 | 27 | Citations (PDF) |
| 150 | Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal | 3.5 | 111 | Citations (PDF) |
| 151 | Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies | 0.7 | 50 | Citations (PDF) |
| 152 | mRNA distribution in adult human brain of GRIN2B, a -methyl--aspartate (NMDA) receptor subunit | 1.4 | 38 | Citations (PDF) |
| 153 | Correlation between PMP-22 messenger mRNA expression and phenotype in hereditary neuropathy with liability to pressure palsies | 4.8 | 39 | Citations (PDF) |
| 154 | Use of cosH1 probe in hereditary neuropathy with liability to pressure palsies: A reliable genetic test for demonstration of identical size of 17p11.2 deletion in unrelated patients | 1.4 | 0 | Citations (PDF) |
| 155 | Expression of high- and low-affinity neurotrophin receptors on human transformed B lymphocytes | 1.8 | 30 | Citations (PDF) |
| 156 | Molecular diagnosis of hereditary neuropathy with liability to pressure palsies (HNPP) by detection of 17p11.2 deletion in Italian patients | 2.9 | 8 | Citations (PDF) |
| 157 | Molecular analysis of three cases with hereditary motor and sensory neuropathy with myelin outfolding | 1.4 | 3 | Citations (PDF) |
| 158 | Insulin-like Growth Factor-II as a Paracrine Growth Factor in Human Neuroblastoma Cells | 2.2 | 56 | Citations (PDF) |
| 159 | Progressive sensory-motor polyneuropathy with tomaculous changes is associated to 17p11.2 deletion. | 1.3 | 23 | Citations (PDF) |
| 160 | Hereditary Neuropathy With Liability to Pressure Palsies and Inherited Brachial Plexus Neuropathy-Two Genetically Distinct Disorders | 2.0 | 21 | Citations (PDF) |
| 161 | Hereditary motor and sensory neuropathy with myelin outfolding: Clinical, genetic and neuropathological study of three cases | 1.3 | 0 | Citations (PDF) |
| 162 | Hereditary motor and sensory neuropathy with myelin outfolding: Clinical, genetic and neuropathological study of three cases | 1.3 | 16 | Citations (PDF) |
| 163 | Impairment of central motor conduction in diabetic patients | 3.0 | 36 | Citations (PDF) |
| 164 | Expression of common acute lymphoblastic leukemia antigen (CD 10) by myelinated fibers of the peripheral nervous system | 1.8 | 9 | Citations (PDF) |
| 165 | Hereditary motor and sensory neuropathy with deafness, mental retardation and absence of large myelinated fibers | 1.3 | 20 | Citations (PDF) |
| 166 | GFAP expression of human Schwann cells in tissue culture | 1.9 | 37 | Citations (PDF) |
| 167 | Schwann cell GFAP expression increases in axonal neuropathies | 1.3 | 27 | Citations (PDF) |
| 168 | Class II antigen expression on human cultured Schwann cells from patients with Charcot-Marie-Tooth disease | 1.4 | 8 | Citations (PDF) |
| 169 | HLA‐DR Schwann cell reactivity in peripheral neuropathies of different origins | 0.7 | 73 | Citations (PDF) |
| 170 | Cerebrospinal fluid and neuropathological study in Devic's syndromeEvidence of intrathecal immune activation | 1.3 | 22 | Citations (PDF) |
| 171 | 504 - Gateway timeout | 1.6 | 19 | Citations (PDF) |
| 172 | Use, tolerability, benefits and side effects of orthotic devices in Charcot-Marie-Tooth disease | 4.4 | 13 | Citations (PDF) |
| 173 | Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes | 3.2 | 9 | Citations (PDF) |
| 174 | Early nociceptive evoked potentials in symptomatic and asymptomatic transthyretin mutation carriers | 1.6 | 2 | Citations (PDF) |
| 175 | ABSTRACT NUMBER: ESOC2026OT182 SCREENING OF VISUAL FIELD DISORDER IN POST-STROKE PATIENTS AND EARLY REHABILITATION | 2.9 | 0 | Citations (PDF) |
| 176 | Motor, Extrapyramidal, and Cognitive Involvement in RFC1 Disease: A Systematic Review and Meta-Analysis. | 1.6 | 2 | Citations (PDF) |
| 177 | A Quantitative Assessment of Upper Limb Motor Function Across Disease Stages in Hereditary Transthyretin Amyloidosis. | 1.9 | 0 | Citations (PDF) |
| 178 | Playing-Related Musculoskeletal Pain in Student and Professional Musicians: Associations with Practice Habits and Healthcare Support | 2.1 | 0 | Citations (PDF) |
| 179 | Triple-M syndrome after immune checkpoint inhibitors: a systematic review of cases-early recognition is critical to survival. | 1.6 | 0 | Citations (PDF) |
| 180 | Patient-Reported Complications and Outcomes of General, Central Neuraxial, and Peripheral Regional Anesthesia in Charcot-Marie-Tooth Disease. | 1.6 | 0 | Citations (PDF) |
